• Ch. Naga Navya Department of Pharmaceutics, J.S.S College of Pharmacy, Mysore, Karnataka, India.
  • Gaurav K Jain Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi India.
  • Vikas Jain Department of Pharmaceutics, J.S.S College of Pharmacy, Mysore, Karnataka, India.




Psoriasis, Biological therapy, Anticytokine therapy, Phototherapy


Psoriasis is adjudged as prototypic papulosquamous skin condition attributed by the erythematous papules (or) plaques. It occurs at any age but commonly seen in age groups of 20–30 and 50–60 years. Psoriasis affects around 2% of the world population. Psoriasis has a broad spectrum of skin indications occurring in different forms with common characteristics. It is clinically classified as non-pustular and pustular psoriasis. Existing therapies include topical therapy, systematic therapy, and phototherapy. Biological drugs and novel immunological factors have been identified as alternative therapy to conventional therapies. These biological drugs show more efficacies with fewer side effects in long-term application.


Download data is not yet available.


King-man HO. Psoriasis. Med Diary 2010;15:5.

Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899 912.

Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb 2016;3:79-82.

Sarıcaoğlu H, Başkan EB. Papüloskuamöz ve eritematöz dermatozlar. ISSUU 2012;12:115-48.

Fitzpatrick’s Dermatology in General Medicine. Available from: https:// www.accessmedicine.mhmedical.com. [Last accessed on 2018 Jan 10].

Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. 2nd ed. Berlin: Springer-Verlag; 2000. p. 585-607.

Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.

van de Kerkhof PC. The woronoff zone surrounding the psoriatic plaque. Br J Dermatol 1998;139:167-8.

Van De Kerkhof PC. Papulosquamous and Eczematous Dermatoses: Psoriasis. Edinburg: Mosby; 2003. p. 125-49.

Gülekon A. Psöriasis ve Benzeri Dermatozlar. İstanbul: Nobel Tıp; 2008. p. 745-60.

Bowcock AM, Barker JN. Genetics of psoriasis: The potential impact on new therapies. J Am Acad Dermatol 2003;49:S51-6.

Habif T. Clinical Dermatology. Edinburgh: Mosby; 2004. p. 209-40.

Sarıfakıoğlu E. Pustular diseases of the hand. Yeni Tıp Dergis 2010;27:138-41.

Erdem H. Psöriatikartritin klinik özellikleri. Romatizma 2000;15:31-8.

Yazici CA. Treatment of nail psoriasis. Turkiye Klinikleri J Dermatol- Special Top 2008;1:31-7.

Dombrowski Y, Schauber J. Cathelicidin LL-37: A defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 2012;21:327-30.

Menter A. Guideline of care for the management of psoriasis and psoriatic arthritis. Dermatol 2009;370:272.

Reisfeld PL. How high is up? Generic prices rise. Cutis 2014;93:6-8.

Mason AR, Mason J, Cork M. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013;3:CD005028.

Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(- 1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003;148:326-33.

Jensen AM, Lladó MB, Skov L, Hansen ER, Larsen JK, Baadsgaard O, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998;139:984-91.

Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC, et al. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004;13:106-12.

Rizova E, Corroller M. Topical calcitriol – studies on local tolerance and systemic safety. Br J Dermatol 2001;144 Suppl 58:3-10.

Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: Results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007;6:428-35.

Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004;15:14-22.

Tzaneva S, Hönigsmann H, Tanew A. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 2003;149:350-3.

Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7.

Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705 11.

Freeman AK, Linowski GJ, Brady C. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564.

Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T, Novak N, et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004;150:1194-7.

Mrowietz U, Wustlich S, Hoexter G, Graeber M, Bräutigam M, Luger T, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3.

van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: A randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006;155:800-7.

Jekler J, Swanbeck G. One-minute dithranol therapy in psoriasis: A placebo-controlled paired comparative study. Acta Derm Venereol 1992;72:449-50.

Oostveen AM, Beulens CA, van de Kerkhof PC, de Jong EM, Seyger MM. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: A prospective comparison of regular day care and day care with telemedicine. Br J Dermatol 2014;170:454-7.

Housman TS, Rohrback JM, Fleischer AB Jr. Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002;46:557-9.

Cooper KD, Oberhelman L, Hamilton TA, Baadsgaard O, Terhune M, LeVee G, et al. UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: Relationship to dose, CD1a-DR+ epidermal macrophage induction, and langerhans cell depletion. Proc Natl Acad Sci U S A 1992;89:8497-501.

Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999;40:893-900.

Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007;357:682-90.

Anderson KL, Feldman SR. A guide to prescribing home phototherapy for patients with psoriasis: The appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. J Am Acad Dermatol 2015;72:868-780.

Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. J Am Acad Dermatol 2002;46:900-6.

Gerber W, Arheilger B, Ha TA, Hermann J, Ockenfels HM. Ultraviolet B 308-nm excimer laser treatment of psoriasis: A new phototherapeutic approach. Br J Dermatol 2003;149:1250-8.

Schiener R, Brockow T, Franke A, Salzer B, Peter RU, Resch KL, et al. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: A randomized controlled trial. Arch Dermatol 2007;143:586-96.

Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann- Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:528-37.

Gottlieb SL, Gilleaudeau P, Johnson R. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442.

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. Methotrexate vs. Placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66.

Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997;133:711-5.

Tanew A, Guggenbichler A, Hönigsmann H. Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682.

Lebwohl M, Drake L, Menter A. Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:44.

Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59:295-315.

Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. Ciclosporin in psoriasis: Effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21.

Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: A study from North India. J Dermatol 2003;30:458-63.

Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, et al. Efficacy of ISA247 in plaque psoriasis: A randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-42.

Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55.

Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-38.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 2012;380:738-46.

Papp KA, Kaufmann R, Thaçi D. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013;27:376.

Feldam S. Treatment of psoriasis. J Eur Acad Dermatol Venereol 2017;31:205.

Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: New implications for associated comorbidities. F1000 Med Rep 2009;1:30.

Anderson PJ. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34:19-22.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.

Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003;25:2487 505.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15.

Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials. Br J Dermatol 2012;166:179-88.

Rider P, Carmi Y, Cohen I. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol 2016;2016:9259646.

Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-27.

Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012;7:e35069.

Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, et al. Selective abrogation of th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 2007;109:1156-64.

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin- 17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.

Ren V, Dao H Jr. Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Investig Dermatol 2013;6:75-80.

Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. Experiences. Br J Dermatol 2004;151:3-15.

Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005;102:2075-80.

Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res 2015;76:215-27.

Claveau D, Chen SL, O’Keefe S, Zaller DM, Styhler A, Liu S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310:752-60.

Houslay M.D, Schafer P, Zhang KY. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;22:1503-19.

Ortiz-Ibáñez K, Alsina MM, Muñoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr 2013;104:304-10.

Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Invest Drugs 2012;4:304-10.

Schieven GL. The biology of p38 kinase: A central role in inflammation. Curr Top Med Chem 2005;5:921-8.

Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L, et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Br J Dermatol 2010;163:1194-204.

Borie DC, Si MS, Morris RE, Reitz BA, Changelian PS. JAK3 inhibition as a new concept for immune suppression. Curr Opin Investig Drugs 2003;4:1297-303.

Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O’Shea JJ, et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42.

EL-Gizaway S, Fadel M, Mourad B, EL-Zahraa F, Elnaby A. Betamethasone dipropionate gel for the treatment of localized plaque psoriasis. Int J Pharm Pharm Sci 2017;9:173-82.

Soliman GM, Osman SK, Hamdan AM. Preparation and evaluation of anthralin biodegradable nanoparticles as a potential delivery system for the treatment of psoriasis. Int J Pharm Pharm Sci 2015;7:36-40.



How to Cite

Navya, C. N., G. K. Jain, and V. Jain. “EXISTING AND NOVEL THERAPIES FOR PSORIASIS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 12, Dec. 2018, pp. 82-87, doi:10.22159/ajpcr.2018.v11i12.27383.



Review Article(s)